Background: The opioid crisis has led to an increase in available donor hearts, although questions remain about the long-term outcomes associated with the use of these organs. Prior studies have relied on historical information without examining the toxicology results at the time of organ offer. The objectives of this study were to examine the long-term survival of heart transplants in the recent era, stratified by results of toxicological testing at the time of organ offer as well as comparing the toxicology at the time of donation with variables based on reported history. Methods: The United Network for Organ Sharing database was requested as well as the donor toxicology field. Between 2007 and 2017, 23 748 adult heart transplants were performed. United Network for Organ Sharing historical variables formed a United Network for Organ Sharing Toxicology Score and the measured toxicology results formed a Measured Toxicology Score. Survival was examined by the United Network for Organ Sharing Toxicology Score and Measured Toxicology Score, as well as Cox proportional hazards models incorporating a variety of risk factors. Results: The number and percent of donors with drug use has significantly increased over the study period ( P <0.0001). Cox proportional hazards modeling of survival including toxicological and historical data did not demonstrate differences in post-transplant mortality. Combinations of drugs identified by toxicology were not associated with differences in survival. Lower donor age and ischemic time were significantly positively associated with survival ( P <0.0001). Conclusions: Among donors accepted for transplantation, neither history nor toxicological evidence of drug use was associated with significant differences in survival. Increasing use of such donors may help alleviate the chronic donor shortage.
This study examined the development of new or changes in donor specific antibodies (DSA) mean-fluorescence intensity (MFI) after SARS-CoV-2 vaccination in 100 kidney and 50 heart transplant recipients. The study was performed when the Center for Disease Control and Prevention (CDC) recommended two doses of Pfizer/BioNTech [BNT162b2] and Moderna [mRNA-1273 SARS-CoV-2] vaccine or 1 dose Johnson & Johnson/Janssen [Ad26.COV2·S] vaccines for full vaccination in transplant recipients. A novel assay bead-based platform for detecting antibodies against 4 domains of the SARS-CoV-2 spike protein to determine vaccine response (SA) and one nucleocapsid protein (NC) to determine prior SARS-CoV-2 infection was utilized. These assays were performed on the multiplex, bead-based platform utilized to assay DSA levels. 61/150 patients (40.7%) had successful vaccination. 18 patients had confirmed SARS-CoV-2 infection based on positive NC assay or previous Covid-19 oropharyngeal swab. 138 patients had no DSA prior to vaccination but 3 heart recipients developed new DSA's. Among 12 patients with known DSA prior to vaccination, 4 developed new DSA's or increased MFI. All 7 patients with new or increased DSA had stable graft function without rejection and had no changes in immunosuppression. All 8 patients with stable post vaccine DSA had stable graft function and immunosuppression was not changed. The presence of DSA before vaccination was associated with subsequent development of increased MFI or new DSA's (p = 0.001). There was no association between pre-vaccine DSA and positive vaccine response (NS). There was no association with successful vaccination or prior SARS-CoV-2 infection and DSA changes (NS).
Patients with continuous-flow left ventricular assist devices have a high risk of gastrointestinal bleeding (GIB) and recurrent bleeding. Studies have shown octreotide can reduce the risk of GIB. This retrospective, case-crossover study, evaluated the efficacy of octreotide for the prevention of recurrent GIB in patients with left ventricular assist devices between August 2008 and October 2018. A total of 32 patients received octreotide and were included in the study. Hospital admission for GIB was evaluated before and after the initiation of octreotide. Each case served as his/her own control. Most patients were on a reduced aspirin dose (56.2%) and had a reduced international normalized ratio goal (59.4%) before starting monthly octreotide. The most common dose of long-acting octreotide was 30 mg every 28 days. Overall, octreotide decreased the frequency of GIB (4.3 vs. 0.9 events/year, p < 0.001). Nineteen (59.4%) patients did not have a subsequent gastrointestinal bleed. Of the 13 patients who rebled after initiation of octreotide, the frequency of events decreased by 2.6 bleeds per patient per year (4.8 vs. 2.2; p = 0.043). In high-risk patients who have failed conventional therapy, octreotide can be useful for the prevention of recurrent GIB.
2 April 2021 in Journal of Engineering and Science in Medical Diagnostics and Therapy
By adopting a physics-physiology integrative approach, this work hypothesizes a mechanistic model of longitudinal wall motion ux(t) at the common carotid artery (CCA) and explores its antegrade amplitude ux0-ante and retrograde amplitude ux0-retro in systole for their clear implications. By examining the findings on ux(t) and other relevant findings on the cardiovascular (CV) physiology in the context of the physical essence of ux(t) and the CV system, a mechanistic model of ux(t) is hypothesized and formulated as a boundary-value problem of nonhomogeneous wave propagation in a semi-infinite domain. With the aid of findings on ux(t) and other related findings in the CV system, a scaling analysis of the boundary-value problem gives rise to two longitudinal arterial indices based on the two amplitudes: longitudinal elasticity Exx at the CCA being estimated from ux0-ante, and ux0-retro as an inverse indicator of the maximum base rotation of the left ventricle (LV) and a positive indicator of longitudinal elasticity at the ascending aorta (AA). The two arterial indices are qualitatively validated by their consistency with the effect of subclinical atherosclerosis and aging on the related parameters in the CV system. The implications of longitudinal elasticity to the LV function and energy transmission in the arterial tree are also discussed.
Aim: This study evaluates whether cardiovascular (CV) parameters derived from noninvasive arterial pulse signals can capture subject-specific physiological characteristics and longitudinal changes in patients with diverse heart diseases. Method: Arterial pulse signals at the radial artery (RA) and carotid artery (CA) were recorded using microfabricated tactile sensors and analyzed with a single-degree-of-freedom time–frequency (SDOF-TF) framework. Key CV parameters, including heart rate (HR), heart rate variability (HRV), respiration rate (RR), respiration modulation (RM), harmonic amplitudes, and normalized arterial pulse waveform (APW), were extracted from measurements at-rest and post-exercise across three visits in eighteen patients with heterogeneous CV conditions. Longitudinal changes in CV parameters within subjects and variability between subjects were assessed. Results: Compared to a healthy reference, patients exhibited altered CV profiles indicative of impaired autonomic regulation. Common trends included reduced HRV, blunted post-exercise CV responses, and attenuation of higher-order harmonics at the RA. CA-derived APW features showed enhanced sensitivity to systolic upstroke slope compared to the RA. Marked inter-subject variability was evident, reflected in at-rest values of key CV parameters and 5min post-exercise responses, highlighting the need for personalized interpretation. Longitudinal measurements revealed mixed effects of exercise on the CV system, likely influenced by concurrent medication and the short observation period. Conclusion: The SDOF-TF framework applied to arterial pulse signals effectively reveals both shared and individualized CV dysfunctions, capturing qualitative harmonic signatures, site-specific differences, and complex parameter interactions not detected by conventional methods, offering potential improvements in diagnosis and treatment monitoring for patients with diverse CV diseases.